Can I read Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy on EtoBox?

Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy by K.N Qureshi; T.R.L Griffiths; M.C Robinson; C Marsh; J.T Roberts; J Lunec; D.E Neal; J.K Mellon is a Medicine article available to read on EtoBox.

What is Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy about?

## Purpose: The prognostic value of p21 and p53 expression was evaluated for patients with muscle-invasive bladder cancer treated by radical radiotherapy. ## Methods and materials: Sixty-eight paraffin-embedded sections from surgically resected tumors taken prior to irradiation were immunostained for p21 and p53. ## Results: Nuclear staining for p21 and p53 was demonstrated in 32/68 (47%) and 46/68 (68%) tumors, respectively. there was no correlation between p21 and p53 immunopositivity in this group (r = 0.067, p = 0.56). patients were stratified into four distinct groups depending on staining for p21 and p53: p21+p53+, p21+p53-, p21-p53+, and p21-p53-. patients with p21+p53+ tumors had the best prognosis with a 3-year survival of 82% compared to 12% for p21-p53+ tumors (p = 0.0031), 29% for p21+p53- tumors (p = 0.0108); and 45% for p21-p53- tumors (p = 0.0375). the p21+p53+ group also demonstrated significantly improved survival when a combined analysis was performed of p21-p53+, p21-p53-, and p21+p53- tumors (3-year survival = 30%, p = 0.0062). in a multivariate model, p21+p53+ tumors (p = 0.0108, relative risk [rr] = 5.18) and complete/partial response (p = 0.0019, rr = 3.76) w

Who reads Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy?

Author

K.N Qureshi; T.R.L Griffiths; M.C Robinson; C Marsh; J.T Roberts; J Lunec; D.E Neal; J.K Mellon

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 0360-3016)

Published

2001

Language

EN

Field

Medicine (Health Sciences)